The purpose of this study was to systemically review the available literature regarding the diagnostic performance of positron emission tomography (PET) using 2- 
Introduction
Thymic epithelial tumors are broadly classified into thymoma and thymic carcinoma and are the most common primary neoplasms of the anterior mediastinum. Tumors of the thymus are a heterogeneous group of tumors, ranging from relatively benign thymomas to highly aggressive carcinomas. The World Health Organization (WHO) published a new histologic classification of thymic epithelial tumors, dividing them into 3 subgroups: low-risk thymomas (types A, AB and B1), high-risk thymomas (types B2 and B3) and thymic carcinomas [1, 2] . Several studies have documented that positron emission tomography (PET) using 2-[
18 F]fluoro-2-deoxy-D-glucose ([ 18 F]FDG) is increasingly important for the imaging technique in the diagnosis, grading malignancy, staging and assessment of response to therapy in patients with thymic epithelial tumors [316] . According to these reports, [ 18 F]FDG-PET is effective in differentiating thymic carcinoma from other entities within the thymus. However, these published reports consisted of clinical trials with small sample size, and we cannot conclude on the diagnostic performance of [ 18 F]FDG-PET in thymic epithelial tumors from these results.
The purpose of this study is to systematically review the available literature regarding the diagnostic performance of [ 18 F]FDG-PET in patients with thymic epithelial tumors, which may contribute to the development of guidelines for the usefulness of PET.
Materials and methods

Search strategy
We addressed the performance of [ 18 F]FDG-PET as a diagnostic test for differentiating thymoma from thymic carcinoma and for the grade of malignancy in thymic epithelial tumors. We performed a systematic search of This paper is available online at http://www.cancerimaging.org. In the event of a change in the URL address, please use the DOI provided to locate the paper. ]FDG-PET for use on humans; sample size with at least 10 participants in each study. Criteria for exclusion were insufficient information to construct 2Â2 contingency tables, and duplicate studies on the same patients. Two reviewers independently selected studies for possible inclusion by checking titles and abstracts. The final decision regarding inclusion was based on the full article. Disagreement was resolved in a consensus meeting.
Results
Characteristics of the published reports
Based on our research criteria, we identified 13 studies that evaluated the diagnostic role of thymic epithelial tumors with [ 18 F]FDG-PET [315] . The characteristics of the studies are presented in Table 1 . The total number of patients in a study ranged from 10 to 49 (median, 18 patients). Reported age ranged from 19 to 85 years, and the population of male patients ranged from 24% to 70%. Most studies comprised both thymoma (n ¼ 231) and thymic carcinoma (n ¼ 86). Mean tumor size range from 47 to 79 mm. Four studies were analyzed according to the Masaoka classification (non-invasive thymoma, invasive thymoma and thymic carcinoma), and 9 studies used a simplified WHO classification (low-risk thymoma, high-risk thymoma and thymic carcinoma). DUR, differential uptake ratio, radioactivity concentration in the region of interest (Bq/mm 3 )/injected dose (Bq)/weight of patients (g); SUV, standardized uptake value; TLR, tumor to lung ratio; T/M ratio is the ratio of the peak SUV of the tumor to the mean SUV of the mediastinum. measurement of [ 18 F]FDG uptake between thymoma and thymic carcinoma [5, 6, 8, 9, 12, 14, 15] , and these 7 studies demonstrated that [ 18 F]FDG uptake in thymic carcinoma was significantly higher than in thymoma. [ 18 F]FDG-PET images are shown in Fig. 1 [16] . In the analysis of the 8 studies according to the WHO classification (Table 3) , the median values for the mean SUV in low-risk thymoma, high-risk thymoma and thymic carcinoma were 3.2 (range, 2.64.0), 5.0 (range, 2.114.1) and 9.2 (range, 7.017.1), respectively. Seven of these 9 studies showed a statistically significant higher [ 18 F]FDG uptake in high-risk thymoma or thymic carcinoma than in low-risk thymoma [6, 813, 15] , and 4 studies revealed that [ 18 F]FDG uptake was significantly higher in thymic carcinoma than in high-risk thymoma [6, 8, 9, 12] . Although 2 studies described the usefulness of [
18 F]FDG-PET for differentiating between low-risk thymoma and high-risk thymoma [12, 15] , 2 studies reported that no statistically significant difference was found among these groups [6, 8] . Fig. 2 [10, 12, 15] . To differentiate thymic carcinoma from thymoma, the sensitivity, specificity and SUV cutoff values were 84.9%, [5] 3.0 AE 1.0 3.8AE 1.3 7.2 AE 2.9* *P50.01 compared with non-invasive thymoma and invasive thymoma El-Bawab et al. [7] 4.75 AE 0.88 NA NA, not available. Luzzi et al. [10] 3.3 AE 0.5 13.5 AE 7.0* *P50.01 compared with low-risk thymoma Kumar et al. [8] 3.0 (1.73.9) 2.1(0.82.8) 7.0 (4.39.2) * *P50.01 compared with thymoma Shibata et al. [9] Type A/AB, B1, B2 and B3; 3.2 AE 0.7, 4.8 AE 2.0, 3.7 AE 1.2, 5.0 AE 1.4
9.2 AE 2.4* *P ¼ 0.048, P ¼ 0.007, P ¼ 0.001, and P ¼ 0.001 compared with type A/AB, B1, B2 and B3, respectively Kaira et al. [12] 2.6 AE 0.9 4.3 AE 1.6** 8.9 AE 3.6* *P50.01 compared with high-risk thymoma. **P50.01 compared with low-risk thymoma Nakajo et al. [13] 3.05 AE 0.55 5.24 AE 2.44* *P ¼ 0.008 compared with low-risk thymoma Igai et al. [14] 3.43 AE 2. 19 8.15 AE 7.88* *P ¼ 0.0084 compared with thymoma Terzi et al. [15] SUV max 4.0 AE 1.7; T/M ratio 2.0 AE 0.5 SUV max 14.1 AE 8.3*; T/M ratio 7.8 AE 5.2** SUV max 17.1 AE 8.5***; T/M ratio 9.6 AE 5.5*** *P ¼ 0.005 and **P50.001 compared with low-risk thymoma. ***No difference was observed between low-risk and high-risk thymoma T/M ratio is the ratio of the peak SUV of the tumor to the mean SUV of the mediastinum. 92.3% and 5.0 in Ref. [5] , 100%, 92% and 6.3 in Ref. [9] , and 63.6%, 91.4% and 6.2 in Ref. [11] . The results for SUV values between low-risk thymoma and high-risk thymoma were 78.3% and 91.3%, respectively, when 4.5 was used as a cutoff [11] .
The role of therapeutic monitoring and outcome
One study reported that high uptake of [
18 F]FDG is significantly associated with poor prognosis [12] . This study included 11 thymic carcinomas among 49 thymic epithelial tumors, and the 11 patients with thymic carcinoma had a significantly high [ 18 [12, 13] . These studies demonstrated that the degree of [ 18 F]FDG uptake in thymic epithelial tumors is closely related to the amount of Glut1, hexokinase II and hypoxic markers.
An in vitro study using a thymic cancer cell line [12] , the uptake of [
18 F]FDG was markedly decreased by the inhibition of Glut1 or hypoxic inducible factor-1alpha (HIF1a), whereas Glut1 upregulation by the induction of HIF1a increased the [ 18 [5] and another study [9] [5, 9, 11] . Moreover, the results in 4 papers confirmed that [
18 F]FDG-PET is useful for differentiating between high-risk thymoma and thymic carcinoma. One paper documented that the SUV values for low-risk thymoma and high-risk thymoma had a sensitivity of 78.3% and specificity of 91.3% using a cutoff value of 4.5 for SUV [11] , but 2 papers found that [ 18 F]FDG-PET could not differentiate high-risk thymoma from low-risk thymoma. Since the SUV value overlaps between low-risk thymoma and high-risk thymoma, [
18 F]FDG-PET may not be a useful diagnostic modality for differentiating these groups. Because previous studies had small sample size, a large-scale study is warranted for assessing whether [
18 F]FDG-PET could be useful for distinguishing tumor subgroups in thymomas.
[ 18 F]FDG-PET imaging of response to chemotherapy or radiation has been reported to be useful for patients with thoracic tumors [17, 18] . A recent study suggests that [
18 F]FDG-PET is useful for monitoring response and outcome after treatment in unresectable thymic epithelial tumors [19] . Although this study consists of only 12 patients who received chemotherapy or radiation because of advanced or metastatic disease, [ 18 F]FDG uptake after treatment in 6 patients with any response was significantly lower than at baseline (P ¼ 0.0017). Moreover, the overall survival after treatment tended to be longer in patients with partial metabolic response compared with those with non-partial metabolic response. As these are preliminary data, further investigation is warranted.
Determination of malignant lesions with [ 18 F]FDG-PET is based on glucose metabolism [20, 21] . The overexpression of Glut1 has been shown to be closely related to [ 18 F]FDG uptake in human cancer [22, 23] . Glut1 is thought to be a possible intrinsic marker of hypoxia, and the expression of Glut1 has been found to be regulated by hypoxia in an HIF-1a-dependent way [24, 25] . HIF1a is considered to support tumor growth by the induction of angiogenesis via the expression of vascular endothelial growth factor (VEGF) and by high and anaerobic metabolic mechanisms [26] . Two papers have reported that the degree of [ 18 F]FDG uptake in thymic epithelial tumors is closely correlated with the amount of Glut1 and hypoxic markers [12, 13] . One of these studies demonstrated that upregulation of Glut1 and HIF-1a was closely associated with [ 18 F]FDG uptake into thymic cancer cells [12] . Biologically, the expression of Glut1 plays a crucial role in the accumulation of [ MET-PET has been used to measure amino acid metabolism in vivo, and therefore a high MET uptake in the tumor cells is thought to reflect an increase in either the transport mechanism of amino acids or protein synthesis [27] . However, MET uptake was not found to differ between thymic carcinoma and thymoma. Recent studies have documented that AC is a useful PET tracer for the detection of slow-growing tumors that cannot be identified using [ 18 F]FDG-PET, such as prostate cancer and well-differentiated adenocarcinoma of the lung [28, 29] . The AC uptake in type A/AB thymoma was significantly higher than that in other histological types. Although AC-PET cannot predict the invasiveness of thymomas assessed by tumor stage, AC-PET has been reported to be useful for predicting the histological type of thymomas [9] . However, we cannot differentiate thymoma from thymic carcinoma using AC-PET. Thus, AC-PET may not be appropriate for differentiating the histological type of thymic epithelial tumors. Compared with METor AC-PET tracer, nowadays, [
18 F]FDG is a better PET tracer for differentiating between thymoma and thymic carcinoma.
Conclusion
This review found that [ 18 F]FDG-PET is a useful radiological modality for differentiating between thymomas and thymic carcinoma. Some papers have reported that thymic carcinoma can be differentiated from thymoma at a diagnostic specificity of more than 90% using an SUV cutoff value more than 5.0. However, [ 
